Bone Therapeutics completes the acquisition of Medsenic and changes its name to Biosenic.
Bone Therapeutics the cell therapy company addressing unmet medical needs in orthopedics and other diseases, announces the closing of its acquisition of a majority participation in Medsenic, a privately held, clinical stage biotech company incorporated in France and specialized in the development of optimized formulations of arsenic Trioxide (ATO) and their applications in serious inflammatory/autoimmune conditions and other potential new indications in related fields
The closing follows the realization of all conditional precedents and the approval of the transaction during Bone Therapeutics’ extraordinary shareholders meeting (‘ESM’) held on October 24, 2022. The ESM has also approved the name change of Bone Therapeutics into BioSenic. The name change will be implemented in the next few days.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins